Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | SVP & General Counsel | August 28, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date August 28, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,557 |
Ending reported balance
After 2026-08-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 22,677 · Balance 60,234 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Row 2 · 2026-08-28 · Sale · Disposed 16,010 · Balance 44,224 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-28 · Sale · Disposed 6,237 · Balance 37,987 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-08-28 · Sale · Disposed 430 · Balance 37,557 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-08-28 · Gift · Disposed 1,000 · Balance 36,557 F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. |
| Non-Qualifed Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.17 · Expires 2030-02-18 | Direct | 0 |
Reported balance
After 2026-08-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-28 · Exercise / conversion · Disposed 22,677 · Balance 0 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Indirect401(k)/SDCP | 5,780 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,780 F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2017 Filed Feb 23, 2017 23:16 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000050 · wf-form4_148789178780845.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,208 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,200 | $93.76 | $112,512.00 |
DisclosureSEC source: 0001022079-17-000024 · wf-form4_148719500803505.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,493 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 22, 2016. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,293 | $93.85 | $121,348.05 |
DisclosureSEC source: 0001022079-17-000024 · wf-form4_148719500803505.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,693 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $55.65 Strike: $55.65 | $834,750.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · derivative · entry 7 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 30,000 | $51.20 Strike: $51.20 | $1,536,000.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · derivative · entry 6 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 15,000 | $92.38 | $1,385,745.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,986 F2 · price: This transaction was executed in multiple trades at prices ranging from $92.06 to $92.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 15,000 | $55.65 | $834,750.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 30,000 | $92.40 | $2,771,850.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,918 F1 · price: This transaction was executed in multiple trades at prices ranging from $92.08 to $92.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 30,000 | $51.20 | $1,536,000.00 |
DisclosureSEC source: 0001022079-17-000009 · wf-form4_148641700170465.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.